-

Bayer Unveils $44 Million Investment in Myerstown, PA Manufacturing Facility, Renewing Commitment to U.S. Innovation, Health and Community

The facility’s new space enhances the company’s Consumer Health production capabilities, embraces automation, and invests in workforce development and community engagement

MYERSTOWN, Pa.--(BUSINESS WIRE)--Today, Bayer proudly celebrated the grand opening of its new 70,000 square foot expansion at its Myerstown facility, following a $44 million investment in 2022. This state-of-the-art facility is a testament to Bayer’s commitment to providing trusted self-care solutions to consumers across North America while advancing meaningful engagement with the local community.

The ribbon-cutting ceremony was attended by Bayer leaders, employees, elected officials, and members of the local community to commemorate this exciting moment for Bayer and Pennsylvania’s Lebanon County. Bayer’s Myerstown site has a rich history dating back over 75 years, and it has now grown to become the largest manufacturing site in Bayer’s Consumer Health network globally, producing brands such as Bayer® Aspirin, Aleve®, Claritin®, One A Day®, Alka-Seltzer Plus®, Midol®, and more.

“Our trusted brands have been helping people live healthier lives for generations. The Myerstown annex will enable us to bring science-backed products to market with more speed and reliability than ever before,” stated Dave Tomasi, President of Bayer’s Consumer Health division in North America. “The expanded facility will further strengthen our commitment to providing safe, effective and high-quality self-care solutions that our consumers and customers can depend on.”

Bayer’s Myerstown facility is set to advance its production capabilities through the integration of modernized technology and streamlined processes, strengthening its ability to reliably deliver science-driven self-care solutions. The new space is designed to move products more efficiently with eight new product packaging lines and automated systems in logistics. With the expansion, Bayer is increasing its ability to swiftly respond to the evolving needs of its consumers and customers.

Bayer’s commitment to growth extends beyond infrastructure and technology; it is an investment in the future of health and wellness for consumers across North America and the people of Myerstown. Along with expanding its physical footprint, the company is dedicated to digitally upskilling its workforce to ensure that employees and the local community are equipped with the knowledge needed to navigate the modern manufacturing landscape. Bayer also plans to welcome local high school educators to tour its Myerstown facilities and operations to bring back information and insights to their school districts.

"We recognize that the key to sustainable growth lies in our people. That’s why we will enable our workforce with the skills needed to adapt to new technologies so they can excel in their careers,” said Divakar Amin, Vice President & Site Manager of Myerstown. “We are proud to contribute to the local economy and foster a vibrant workforce made up of many Myerstown locals. Together, we are building a brighter future for Bayer and the communities we serve.”

As Bayer continues to innovate and empower everyday health, the company remains steadfast in its mission to elevate the quality of life for people around the world through trusted health and nutrition solutions.

“Our commitment to credible science and consumer advocacy drives our mission Health for all, Hunger for none,” said Michael Sullivan, Senior Vice President of Product Supply for Bayer’s Consumer Health division in North America. “We are excited about the positive impact this investment will have as we are paving the way for a healthier future where everyone has access to the products that they need to support their well-being.”

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Contacts

Media Contact:
Hannah Schwartz
Email: hannah.schwartz@bayer.com
Cell: 862-783-8442

Bayer


Release Versions

Contacts

Media Contact:
Hannah Schwartz
Email: hannah.schwartz@bayer.com
Cell: 862-783-8442

More News From Bayer

Bayer welcomes the U.S. Supreme Court decision to review the Durnell case in the Roundup™ litigation

LEVERKUSEN--(BUSINESS WIRE)--The U.S. Supreme Court today announced that it will review the Durnell Roundup™ case. Monsanto petitioned the court to hear Durnell in April 2025 and address the split in authority among federal circuit courts on the application of federal preemption, a cross-cutting issue in the Roundup™ litigation. The company expects a decision on the merits during the Court’s 2026 session, which ends in June. “The Supreme Court decision to take the case is good news for U.S. far...

Bayer Accelerates Pharma Growth on High-Value Portfolio

SAN FRANCISCO--(BUSINESS WIRE)--On the occasion of the 44th J.P. Morgan Healthcare Conference in San Francisco, Bayer AG today unveiled the strategic focus for its Pharmaceuticals Division in 2026. Capitalizing on new launch momentum, the company will drive significant global regulatory expansions and market penetration across its pharmaceutical portfolio. High-value commercial products and an accelerating modality-rich pipeline across oncology, cardiology, neurology, and immunology have firmly...

Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Menopause

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced it has partnered with actress and menopause advocate Gabrielle Union-Wade on the ‘Life Doesn’t Stop for a Hot Flash’ campaign, which speaks to women with moderate to severe hot flashes due to menopause. The campaign encourages women to have an open and honest conversation with their healthcare provider about their hot flash experiences and learn about treatment options, including Lynkuet® (elinzanetant) 60mg capsules, a hormone-free prescri...
Back to Newsroom